2025-11-07T09:11:57-06:00 2025-06-30 431985162 SMITH SULLIVAN & BROWN PC 80 FLANDERS ROAD SUITE 302 WESTBOROUGH MA 01581 990 2024-07-01 471981973 COHEN VETERANS BIOSCIENCE INC COHE 8886277345 82 WENDELL AVENUE 100 PITTSFIELD MA 01201 MAGALI HAAS MD PHD BOARD CHAIR 8886277345 2025-11-07 1 0 SANDRA M BROWN CPA P01614103 5088717178 2025-11-05 2024 2025-03-06 01:10:19Z MAGALI HAAS MD PHD 82 WENDELL AVENUE 100 PITTSFIELD MA 01201 3369809 0 X WWW.COHENVETERANSBIOSCIENCE.ORG X 2014 MA BIOMEDICAL RESEARCH AND TECHNOLOGY ORGANIZATION DEDICATED TO ADVANCING BRAIN HEALTH BY FAST-TRACKING PRECISION DIAGNOSTICS AND TAILORED THERAPEUTICS. 4 3 22 0 0 0 8131591 1001859 0 0 51935 2343457 194225 24493 8377751 3369809 31373 0 0 0 8107509 279314 0 0 0 5941028 1098447 14079910 1377761 -5702159 1992048 3075275 1835419 3105844 98368 -30569 1737051 X COHEN VETERANS BIOSCIENCE, INC. ("CVB") IS A NON-PROFIT 501(C)(3) BIOMEDICAL RESEARCH AND TECHNOLOGY ORGANIZATION DEDICATED TO ADVANCING BRAIN HEALTH BY FAST-TRACKING PRECISION DIAGNOSTICS AND TAILORED THERAPEUTICS. 0 1 506116 CVB'S BOARD OF DIRECTORS VOTED FOR AN ORDERLY WIND DOWN OF OPERATIONS EFFECTIVE MAY 17, 2024. DECEMBER 31, 2024 WAS THE FINAL DAY OF CONTINUING OPERATIONS. SUBSEQUENT TO THIS DATE, THE ORGANIZATION DOES NOT ANTICIPATE ANY ADDITIONAL REVENUE, AND COSTS WILL LARGELY BE RELATED TO THE DISSOLUTION PROCESS AND EFFORTS TO TRANSFER THE INTELLECTUAL PROPERTY AND RESEARCH TO OTHER CHARITABLE ORGANIZATIONS. THE ORGANIZATION HAS SUFFICIENT RESOURCES TO COVER ALL ANTICIPATED COSTS THROUGH DISSOLUTION. 506116 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 18 0 22 1 0 0 0 0 0 0 0 0 0 0 0 0 X 4 3 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA NY X X GELMAN ROSENBERG AND FREEDMAN CPA 3019519090 4550 MONTGOMERY AVENUE SUITE 650N BETHESDA MD 20814 DAVID BIONDI BOARD SECRETARY 1.00 X X 0 0 0 DAVE DEMARCO BOARD TREASURER 1.00 X X 0 0 0 MAGALI HAAS MD PHD BOARD CHAIR & FORMER CEO 60.00 X X 796526 0 9424 FRANK LARKIN VICE CHAIR 1.00 X X 0 0 0 PETER HOEHN FORMER CEO 40.00 X 322853 0 21495 NICOLE HARMON FORMER PRESIDENT 40.00 X 350316 0 21253 LEE LANCASHIRE FORMER CHIEF INFORMATION O 40.00 X 390648 0 57821 ALLYSON GAGE PHD FORMER CHIEF MEDICAL OFFIC 40.00 X 445608 0 16631 EVGENY RAKHMATULIN FORMER CHIEF TECHNOLOGY OF 40.00 X 297253 0 19924 MICHAEL CARSON FORMER HEAD OF COMMUNICATI 40.00 X 171793 0 891 MARYAN ZIRKLE FORMER EXECUTIVE DIRECTOR, 40.00 X 242170 0 12325 RAGINI VERMA FORMER HEAD OF BIOMAKERS & 40.00 X 223732 0 13786 MARK ZERVAS FORMER HEAD OF DISCOVERY A 40.00 X 204197 0 21603 LAUREN GOLDSMITH FORMER SENIOR DIRECTOR, CO 40.00 X 185810 0 12142 3630906 0 207295 17 0 1 0 MORGAN LEWIS & BOCKIUS LLP 1701 MARKET STREET PHILADELPHIA PA 19103 LEGAL SERVICES 386113 GRF CPA'S & ADVISORS 4550 MONTGOMERY AVENUE SUITE 800 N BETHESDA MD 20814 ACCOUNTING SERVICES 265527 SAMPLED 30 KNIGHTSBRIDGE RD BLDG 3 PISCATAWAY NJ 08854 DATA ANALYSIS & STORAGE 185918 METACELL 1 BROADWAY 14TH FL CAMBRIDGE MA 02142 DATA SERVICES 127558 4 1001859 1001859 43457 43457 2300000 0 2300000 2300000 2300000 OTHER INCOME 900099 24493 24493 24493 3369809 24493 0 2343457 206700 206700 18354 18354 39788 39788 13012 13012 1460 1460 59091 59091 136625 136625 2667 2667 93927 35302 58625 401217 399331 1886 162733 162733 10045 10045 10000 10000 84920 71483 13437 137222 137222 1377761 506116 871645 0 402891 157497 1247450 1652520 52 65574 0 168949 1190359 25402 3075275 1835419 2172902 98368 932942 0 3105844 98368 X -30569 1737051 -30569 1737051 3075275 1835419 X 1992048 -224428 X X 0 0 0 X 16160581 17941055 9750042 8131591 1001859 52985128 16160581 17941055 9750042 8131591 1001859 52985128 49424297 3560831 59585 28608 223966 51935 43457 407551 32104 112735 364187 194225 24493 727744 54120423 0.06580 0.08860 AFTER MORE THAN TEN YEARS OF OPERATION, COHEN VETERANS BIOSCIENCE (CVB) HAD SUBSTANTIALLY ACHIEVED ITS FOUNDING MISSION TO DEVELOP AND LEVERAGE ADVANCED ARTIFICIAL INTELLIGENCE (AI)/MACHINE LEARNING (ML) AND BIOMARKER TECHNOLOGIES TO ACCELERATE THE DISCOVERY OF DIAGNOSTICS AND THERAPEUTICS FOR BRAIN DISORDERS SUCH AS POST-TRAUMATIC STRESS DISORDER (PTSD) AND TRAUMATIC BRAIN INJURY (TBI).WHEN CVB WAS ESTABLISHED IN 2014, MANY OF THE TECHNOLOGIES REQUIRED TO ACHIEVE THIS MISSION PARTICULARLY IN AI/ML AND BIOMARKER SCIENCE WERE NASCENT OR NON-EXISTENT. OVER THE ENSUING DECADE, CVB PLAYED A KEY ROLE IN BUILDING FOUNDATIONAL SCIENTIFIC, DATA, AND COMPUTATIONAL INFRASTRUCTURE TO ENABLE PREDICTIVE DISEASE MODELING AND TRANSLATIONAL RESEARCH IN BRAIN HEALTH. ADDITIONALLY, WE DROVE NATIONAL ADVOCACY EFFORTS TO SUPPORT BRAIN DISEASE INVESTMENT AND PUBLISHED RESEARCH ROADMAPS FOR PRECISION MEDICINE RESEARCH IN PTSD AND TBI.BY 2023, THE RAPID ADVANCEMENT OF LARGE LANGUAGE MODELS (LLMS) AND RELATED AI INNOVATIONS REVOLUTIONIZED THE FIELD, PROVIDING SCALABLE TOOLS THAT COULD NOW ACHIEVE AT A GLOBAL LEVEL WHAT CVB HAD LONG SOUGHT TO ENABLE. IN PARALLEL, THE EMERGENCE OF ROBUST BIOMARKER DISCOVERY PLATFORMS AND MULTI-INSTITUTIONAL DATA COLLABORATIONS INDICATED THAT THE FIELD HAD MATURED TO A STAGE WHERE CVB'S MISSION COULD BE EFFECTIVELY CARRIED FORWARD BY OTHER CAPABLE ORGANIZATIONS. SUBSEQUENTLY, A SIGNIFICANT AMOUNT OF CAPITAL HAS BEGUN TO FLOW TO BOTH THE PRIVATE SECTOR AND ACADEMIC INSTITUTIONS THAT REPLACES THE NEED FOR CVB'S CATALYTIC ROLE.RECOGNIZING BOTH THE SUCCESSFUL COMPLETION OF ITS CORE MISSION OBJECTIVES AND INCREASING FUNDING UNCERTAINTIES FOR NONPROFIT RESEARCH ORGANIZATIONS, THE CVB BOARD OF DIRECTORS DETERMINED AT THE END OF FY24 THAT IT WAS IN THE BEST INTEREST OF THE MISSION, OUR STAFF AND THE PUBLIC GOOD TO WIND DOWN OPERATIONS AND PROCEED WITH DISSOLUTION. AS PART OF THIS PROCESS, CVB COMMITTED TO TRANSFER ITS FOUNDATIONAL ASSETS, DATA RESOURCES, AND INTELLECTUAL PROPERTY TO PARTNER ORGANIZATIONS POSITIONED TO SCALE AND SUSTAIN THEIR IMPACT FOR CONTINUED ADVANCEMENT IN BRAIN DISORDER RESEARCH AND EXECUTION OF THE ROADMAPS.AS A RESULT OF THESE FACTS AND CIRCUMSTANCES, CVB DID NOT ACCEPT DONATIONS IN FY 2025, OTHER THAN ONE GRANT TO ASSIST WITH WINDING DOWN COSTS. SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: HRA FORFEITURES - 2020 AMOUNT: $ 28,475. STIMULUS/COVID CREDITS - 2020 AMOUNT: $ 3,629. 2021 AMOUNT: $ 2,480. OTHER REFUNDS - 2021 AMOUNT: $ 110,255. 2023 AMOUNT: $ 53,200. OTHER INCOME - 2022 AMOUNT: $ 37,205. 2023 AMOUNT: $ 1,481. 2024 AMOUNT: $ 24,493. GRANT REFUNDS - 2022 AMOUNT: $ 326,982. 2023 AMOUNT: $ 139,544. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 1643751 1643751 232188 58047 0 0 1000000 917068 853996 232188 3003252 4504878 90000 120000 60000 270000 250000 229267 213499 58047 750813 1126220 X X X 1 0 0 0 0 0 0 0 0 MAGALI HAAS MD PHD BOARD CHAIR & FORMER CEO 430707 0 208173 0 157646 0 9424 0 0 0 805950 0 0 0 ALLYSON GAGE PHD FORMER CHIEF MEDICAL OFFIC 186680 0 132081 0 126847 0 11289 0 5342 0 462239 0 0 0 LEE LANCASHIRE FORMER CHIEF INFORMATION O 157967 0 135259 0 97422 0 6854 0 50967 0 448469 0 0 0 NICOLE HARMON FORMER PRESIDENT 144088 0 104690 0 101538 0 5896 0 15357 0 371569 0 0 0 PETER HOEHN FORMER CEO 175353 0 87500 0 60000 0 9518 0 11977 0 344348 0 0 0 EVGENY RAKHMATULIN FORMER CHIEF TECHNOLOGY OF 135218 0 78795 0 83240 0 8323 0 11601 0 317177 0 0 0 MARYAN ZIRKLE FORMER EXECUTIVE DIRECTOR, 114014 0 49584 0 78572 0 6931 0 5394 0 254495 0 0 0 RAGINI VERMA FORMER HEAD OF BIOMAKERS & 129055 0 61400 0 33277 0 7798 0 5988 0 237518 0 0 0 MARK ZERVAS FORMER HEAD OF DISCOVERY A 98181 0 46900 0 59116 0 6134 0 15469 0 225800 0 0 0 LAUREN GOLDSMITH FORMER SENIOR DIRECTOR, CO 110937 0 74873 0 0 0 6748 0 5394 0 197952 0 0 0 MICHAEL CARSON FORMER HEAD OF COMMUNICATI 94682 0 47300 0 29811 0 0 0 891 0 172684 0 0 0 PART I, LINE 4A THE ORGANIZATION CONCLUDED ITS MISSION AND BEGAN AN ORDERLY WIND DOWN PROCESS IN 2024. EFFECTIVE MAY 17, 2024, ALL EMPLOYEES WERE TERMINATED. EVERY EMPLOYEE RECEIVED SEVERANCE COMPENSATION EQUAL TO TWO WEEKS OF PAY FOR EACH ONE FULL YEAR OF SERVICE, CAPPED AT 16 WEEKS OF COMPENSATION. IN CALENDAR YEAR 2024, THE ORGANIZATION MADE THE FOLLOWING SEVERANCE PAYMENTS TO THE INDIVIDUALS LISTED ABOVE: - MAGALI HAAS, CHAIR & FORMER CEO $157,646 - ALLYSON GAGE, FORMER CHIEF MEDICAL OFFICER $126,847 - LEE LANCASHIRE, FORMER CHIEF INFORMATION OFFICER $97,421 - NICOLE HARMON, FORMER PRESIDENT $101,538 - PETER HOEHN, FORMER CHIEF EXECUTIVE OFFICER $60,000 - EVGENY RAKHMATULIN, FORMER CHIEF TECHNOLOGY OFFICER $83,240 - MARYAN ZIRKLE, FORMER EXECUTIVE DIRECTOR, BRAINCOMMONS $78,572 - RAGINA VERMA, HEAD OF BIOMARKERS & CLINICAL DEVELOPMENT $33,277 - MARK ZERVAS, HEAD OF DISCOVERY & PRECLINICAL RESEARCH $59,116 - LAUREN GOLDSMITH, SR. DIRECTOR, CONTRACTS & GRANTS MGT. $74,873 - MICHAEL CARSON, HEAD OF COMMUNICATIONS $29,811 FORM 990, PART III, LINE 3 STARTING JUNE 2024, CVB INITIATED A WIND-DOWN OF ALL PROGRAM ACTIVITIES. PUBLIC ASSETS, SUCH AS SOFTWARE, DATASETS AND BIOSAMPLES, GENERATED BY CVB HAVE BEEN OR WILL BE PLACED IN PUBLIC REPOSITORIES (E.G. GITHUB, BIOSEND) AND MAY BE TRACKED VIA OUR WEBSITE. ALL PUBLICATIONS GENERATED BY CVB STAFF ARE PUBLISHED IN OPEN-ACCESS JOURNALS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS REVIEWED BY THE ORGANIZATION'S OUTSOURCED CFO AND TREASURER AND THEN REVIEWED, AUTHORIZED AND SIGNED BY THE ORGANIZATION'S CHAIR. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD OF DIRECTORS REQUIRES AN ANNUAL DECLARATION FROM ALL BOARD MEMBERS AND SENIOR MANAGEMENT AS TO THE EXISTENCE AND DISCLOSURE OF ANY POTENTIAL CONFLICTS OF INTEREST. THE BOARD MEMBERS SIGN A DISCLOSURE STATEMENT. ANY POTENTIAL CONFLICTS ARE DISCUSSED BY THE DIS-INTERESTED BOARD MEMBERS, WHILE THE PARTY IN POTENTIAL CONFLICT IS REQUIRED TO LEAVE THE ROOM. BOARD MEETING MINUTES WILL DOCUMENT THE DISCUSSION AND DECISION MAKING PROCESS. IN THE EVENT OF A POTENTIAL CONFLICT, PROCEDURES TO OBTAIN COMPETITIVE BIDS AND DILIGENCE ON FAIR MARKET VALUE WILL BE ESTABLISHED. FORM 990, PART VI, SECTION B, LINE 15 CVB'S EXECUTIVE COMPENSATION PROGRAM IS ADMINISTERED BY THE BOARD OF DIRECTORS. THE BOARD IS RESPONSIBLE FOR ESTABLISHING AND MAINTAINING A COMPETITIVE COMPENSATION PROGRAM FOR THE KEY EXECUTIVES OF THE ORGANIZATION. THE BOARD MEETS AS NEEDED TO REVIEW THE COMPENSATION PROGRAM AND MAKE RECOMMENDATIONS FOR ANY CHANGES, AS APPROPRIATE. A PERFORMANCE EVALUATION IS CONDUCTED AND REVIEWED EACH YEAR AND IS INTENDED TO ENSURE THAT THE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. FOLLOWING THIS REVIEW, THE BOARD REVIEWS AND APPROVES, FOR SELECTED KEY EXECUTIVES, BASE SALARIES AND ANNUAL INCENTIVE OPPORTUNITY ADJUSTMENTS, AND OBJECTIVES AND GOALS UPCOMING YEAR'S ANNUAL INCENTIVE PLAN. THE BOARD REVIEWS AND RECOMMENDS TO THE BOARD SALARY APPROVAL AND INCENTIVE AWARDS FOR THE CEO/PRESIDENT AND SELECTED KEY SENIOR STAFF. FORM 990, PART VI, SECTION C, LINE 19 UPON REQUEST AND FORMS AVAILABLE THROUGH CHARITY NAVIGATOR WEBSITE AS WELL. FORM 990, PART XI, LINE 9: LOSS ON LEASE TERMINATION -224,428. FORM 990, PAGE 12, PART XII, LINE 2B THE FINANCIAL STATEMENTS WERE AUDITED THROUGH 12/31/2024, THE CEASE OPERATIONS DATE. THERE IS NOT A FORMAL AUDIT COMMITTEE. THE FULL BOARD OF DIRECTORS OVERSEES THE AUDIT PROCESS.